{"transactions":[{"id":4622856,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T20:10:05.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":12394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":83848,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":12394},"source":{"system":"sec-edgar","filing":"0001810417-26-000023","document":"form4-09182026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000023/form4-09182026_040901.xml","form_type":"4"}},{"id":4622855,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-18T20:10:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":12394,"price":16.3335,"value":202437.399,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000023","document":"form4-09182026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000023/form4-09182026_040901.xml","form_type":"4"}},{"id":4622854,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-18T20:10:05.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":12394,"price":9.88,"value":122452.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."}],"balance_after":52294,"source":{"system":"sec-edgar","filing":"0001810417-26-000023","document":"form4-09182026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000023/form4-09182026_040901.xml","form_type":"4"}},{"id":4615839,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-11T20:10:06.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":10185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":105815,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":10185},"source":{"system":"sec-edgar","filing":"0001810417-26-000021","document":"form4-09112026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000021/form4-09112026_040901.xml","form_type":"4"}},{"id":4615838,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T20:10:06.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":10185,"price":17.6197,"value":179456.6445,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000021","document":"form4-09112026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000021/form4-09112026_040901.xml","form_type":"4"}},{"id":4615837,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T20:10:06.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":10185,"price":8.04,"value":81887.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."}],"balance_after":50085,"source":{"system":"sec-edgar","filing":"0001810417-26-000021","document":"form4-09112026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000021/form4-09112026_040901.xml","form_type":"4"}},{"id":681494,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":31031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":96242,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":31031},"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681493,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":2876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":127273,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":2876},"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681492,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":37945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":130149,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":37945},"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681491,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":31031,"price":20.0549,"value":622323.6019,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681490,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":31031,"price":9.88,"value":306586.28,"ownership":{"direct":true},"balance_after":70931,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681489,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":3749,"price":19.9419,"value":74762.1831,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681488,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":37945,"price":19.8533,"value":753333.4685,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":43649,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681487,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":2876,"price":9.88,"value":28414.88,"ownership":{"direct":true},"balance_after":81594,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681486,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":37945,"price":9.88,"value":374896.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."}],"balance_after":78718,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":740054,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:36:45.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":138,"price":13.1,"value":1807.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":40773,"source":{"system":"sec-edgar","filing":"0001810417-26-000016","document":"form4-06122026_080641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000016/form4-06122026_080641.xml","form_type":"4"}},{"id":763904,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:13.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":39900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40323,"source":{"system":"sec-edgar","filing":"0001810417-26-000014","document":"form4-05262026_040507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000014/form4-05262026_040507.xml","form_type":"4"}},{"id":784822,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-11T20:05:09.000Z","date":"2026-05-07","kind":"exercise","planned":true,"acquired":false,"shares":18606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":168094,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":18606},"source":{"system":"sec-edgar","filing":"0001810417-26-000012","document":"form4-05112026_040503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000012/form4-05112026_040503.xml","form_type":"4"}},{"id":784821,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-11T20:05:09.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":18606,"price":24.1222,"value":448817.6532,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":423,"source":{"system":"sec-edgar","filing":"0001810417-26-000012","document":"form4-05112026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000012/form4-05112026_040503.xml","form_type":"4"}},{"id":784820,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-11T20:05:09.000Z","date":"2026-05-07","kind":"exercise","planned":true,"acquired":true,"shares":18606,"price":9.88,"value":183827.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":19029,"source":{"system":"sec-edgar","filing":"0001810417-26-000012","document":"form4-05112026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000012/form4-05112026_040503.xml","form_type":"4"}},{"id":788548,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":116000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788547,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":8900,"price":22.5745,"value":200913.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":423,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788546,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":9219,"price":21.3698,"value":197008.1862,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":9323,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788545,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":2700,"price":20.76,"value":56052.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":18542,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788544,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":12347,"price":19.2835,"value":238093.3745,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":21242,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788543,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":13834,"price":18.5525,"value":256655.285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":33589,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788542,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":47000,"price":8.04,"value":377880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":47423,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":795784,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-01T20:37:50.000Z","date":"2026-04-30","kind":"sale","planned":true,"acquired":false,"shares":8457,"price":13.2261,"value":111853.1277,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $12.61 to $13.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":423,"source":{"system":"sec-edgar","filing":"0001810417-26-000008","document":"form4-05012026_080546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000008/form4-05012026_080546.xml","form_type":"4"}},{"id":795783,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-01T20:37:50.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":8458,"price":13.0925,"value":110736.365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $12.74 to $13.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":8880,"source":{"system":"sec-edgar","filing":"0001810417-26-000008","document":"form4-05012026_080546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000008/form4-05012026_080546.xml","form_type":"4"}},{"id":816590,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T19:14:43.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":1780,"price":17.5674,"value":31269.972,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $17.39 to $17.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":17338,"source":{"system":"sec-edgar","filing":"0001810417-26-000006","document":"form4-04032026_070439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000006/form4-04032026_070439.xml","form_type":"4"}},{"id":816589,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T19:14:43.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":6200,"price":17.0247,"value":105553.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $16.385 to $17.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":19118,"source":{"system":"sec-edgar","filing":"0001810417-26-000006","document":"form4-04032026_070439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000006/form4-04032026_070439.xml","form_type":"4"}},{"id":816588,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T19:14:43.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":7479,"price":16.8259,"value":125840.9061,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $16.45 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":25318,"source":{"system":"sec-edgar","filing":"0001810417-26-000006","document":"form4-04032026_070439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000006/form4-04032026_070439.xml","form_type":"4"}},{"id":816587,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T19:14:43.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":500,"price":15.858,"value":7929.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $15.24 to $16.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":32797,"source":{"system":"sec-edgar","filing":"0001810417-26-000006","document":"form4-04032026_070439.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000006/form4-04032026_070439.xml","form_type":"4"}},{"id":824203,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-31T20:10:35.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":false,"shares":24200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":24200,"derivative":{"underlying":"Common Stock","underlying_shares":24200},"source":{"system":"sec-edgar","filing":"0001810417-26-000004","document":"form4-03312026_080330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000004/form4-03312026_080330.xml","form_type":"4"}},{"id":824202,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:10:35.000Z","date":"2026-03-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":8241,"price":13.89,"value":114467.49,"ownership":{"direct":true},"balance_after":33297,"source":{"system":"sec-edgar","filing":"0001810417-26-000004","document":"form4-03312026_080330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000004/form4-03312026_080330.xml","form_type":"4"}},{"id":824201,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:10:35.000Z","date":"2026-03-28","kind":"exercise","planned":false,"acquired":true,"shares":24200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":41538,"source":{"system":"sec-edgar","filing":"0001810417-26-000004","document":"form4-03312026_080330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000004/form4-03312026_080330.xml","form_type":"4"}},{"id":874364,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T21:22:04.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":105000,"derivative":{"exercise_price":17.64,"expiration_date":"2036-02-26","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001810417-26-000002","document":"form4-03022026_090301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000002/form4-03022026_090301.xml","form_type":"4"}},{"id":971291,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-12T21:17:34.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":155,"price":4.1,"value":635.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 417 additional shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":17338,"source":{"system":"sec-edgar","filing":"0001470831-25-000409","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000147083125000409/form4.xml","form_type":"4"}},{"id":1186550,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-01T20:11:39.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":false,"shares":24200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":48400,"derivative":{"underlying":"Common Stock","underlying_shares":24200},"source":{"system":"sec-edgar","filing":"0001578563-25-000198","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856325000198/primary_doc.xml","form_type":"4"}},{"id":1186549,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-01T20:11:39.000Z","date":"2025-03-28","kind":"tax_withholding","planned":false,"acquired":false,"shares":7285,"price":8.46,"value":61631.1,"ownership":{"direct":true},"balance_after":16921,"source":{"system":"sec-edgar","filing":"0001578563-25-000198","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856325000198/primary_doc.xml","form_type":"4"}},{"id":1186548,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-01T20:11:39.000Z","date":"2025-03-28","kind":"exercise","planned":false,"acquired":true,"shares":24200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":24206,"source":{"system":"sec-edgar","filing":"0001578563-25-000198","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856325000198/primary_doc.xml","form_type":"4"}},{"id":1290822,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-30T22:43:52.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":163000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":163000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":163000},"source":{"system":"sec-edgar","filing":"0001578563-25-000028","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856325000028/primary_doc.xml","form_type":"4"}},{"id":1433737,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-08-14T20:11:10.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":72600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock upon the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":72600,"derivative":{"underlying":"Common Stock","underlying_shares":72600},"source":{"system":"sec-edgar","filing":"0001578563-24-000364","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856324000364/primary_doc.xml","form_type":"4"}},{"id":1433736,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-14T20:11:10.000Z","date":"2024-08-13","kind":"grant","planned":false,"acquired":true,"shares":186700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":186700,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":186700},"source":{"system":"sec-edgar","filing":"0001578563-24-000364","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856324000364/primary_doc.xml","form_type":"4"}},{"id":1857336,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-13T20:41:21.000Z","date":"2023-06-09","kind":"purchase","planned":false,"acquired":true,"shares":511,"price":3.42,"value":1747.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":1262,"source":{"system":"sec-edgar","filing":"0001628280-23-021962","document":"wk-form4_1686688870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000162828023021962/wk-form4_1686688870.xml","form_type":"4"}},{"id":1889240,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-17T11:44:53.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":2.75,"exercise_date":"2024-05-15","expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-23-018557","document":"wk-form4_1684323885.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000162828023018557/wk-form4_1684323885.xml","form_type":"4"}},{"id":2013719,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-15T21:19:43.000Z","date":"2023-02-13","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":2.98,"expiration_date":"2033-02-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001628280-23-003708","document":"wf-form4_167649596254341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000162828023003708/wf-form4_167649596254341.xml","form_type":"4"}},{"id":2140516,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-07T20:01:47.000Z","date":"2022-10-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":3.97,"exercise_date":"2023-10-05","expiration_date":"2032-10-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001628280-22-026157","document":"wf-form4_166517288861221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000162828022026157/wf-form4_166517288861221.xml","form_type":"4"}},{"id":2340016,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-10T22:50:14.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest in full on March 8, 2023, subject to the Reporting Person's continued service through the vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.7,"expiration_date":"2032-03-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001578563-22-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856322000006/primary_doc.xml","form_type":"4"}},{"id":2340015,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-10T22:50:14.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date."}],"balance_after":400000,"derivative":{"exercise_price":0.7,"expiration_date":"2032-03-08","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001578563-22-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000157856322000006/primary_doc.xml","form_type":"4"}},{"id":2473708,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-12-14T22:17:13.000Z","date":"2021-12-10","kind":"purchase","acquired":true,"shares":955,"price":1.57,"value":1499.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":9004,"source":{"system":"sec-edgar","filing":"0001879785-21-000039","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000187978521000039/edgar.xml","form_type":"4"}},{"id":2892266,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T21:08:49.000Z","date":"2021-01-26","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date."}],"balance_after":110000,"derivative":{"exercise_price":3.32,"expiration_date":"2031-01-26","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001192482-21-000120","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000119248221000120/edgar.xml","form_type":"4"}},{"id":2946835,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2020-12-14T21:12:31.000Z","date":"2020-12-10","kind":"purchase","acquired":true,"shares":5095,"price":2.278,"value":11606.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":8049,"source":{"system":"sec-edgar","filing":"0001192482-20-000818","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000119248220000818/edgar.xml","form_type":"4"}},{"id":3113603,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CFO"}}],"security":"Common Stock","published_at":"2020-06-12T01:08:10.000Z","date":"2020-06-10","kind":"purchase","acquired":true,"shares":2954,"price":2.278,"value":6729.212,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan."}],"balance_after":2954,"source":{"system":"sec-edgar","filing":"0001192482-20-000486","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000119248220000486/edgar.xml","form_type":"4"}}]}